BridgeBio reports Q3 2026 loss of $0.42 per share, revenue $353M and strong Attruby growth

BridgeBio Pharma posted a third‑quarter loss of $0.42 per share, beating analysts' expectations. Revenue came in at $353.17 million, well above forecasts. U.S. Attruby net product revenue rose 14% sequentially to $253.2 million, and the company ended the quarter with about $1.5 billion in cash. Management reaffirmed a $4 billion peak‑year sales target for Attruby and highlighted upcoming FDA decisions, including a November 27, 2026 action date for BBP‑418.

UBS kept a Buy rating and a $92.00 price target, citing the strong Attruby sales and narrowed loss (source). The cash balance is described as sufficient to fund upcoming product launches and pipeline milestones (source).

  • 1Q3 loss was $0.42 per share, beating estimates by $0.18.
  • 2Revenue was $353.17 million, exceeding forecasts by $61.96 million.
  • 3U.S. Attruby net product revenue was $253.2 million, up about 14% quarter‑on‑quarter and 134% year‑over‑year.
  • 4Cash, cash equivalents and marketable securities totaled about $1.5 billion at quarter end.
  • 5Management expects Attruby to meet or exceed a $4 billion peak‑year sales assumption.
  • 6BBP‑418 has an FDA action date of November 27, 2026.

Sources